Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai's High Dose Aricept Beats Expectations, But Lack Of Solutions Plague Mid-term Forecast

This article was originally published in PharmAsia News

Executive Summary

TOKYO - A higher-dose Aricept anti-Alzheimer treatment U.S. FDA approved this summer is set to be a core revenue contributor for Eisai through its business year ending next March and on, and if its endotoxin antagonist eritoran for severe sepsis is approved, the growth momentum could continue through 2012, according to Eisai and analysts

You may also be interested in...



Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept

TOKYO - Eisai will launch a "substantial marketing campaign" behind the recent U.S. approval of high-dose Aricept (donepezil) as the company races to move moderate to severe Alzheimer's disease patients that could benefit from higher doses of the drug from the 10 mg dosage to the newly approved 23 mg dosage ahead of Aricept 10 mg's November 2010 patent loss

Eisai Seeks Global Approval For Cancer Agent Eribulin As Aricept Patent Expiration Looms Near

TOKYO - Eisai March 31 said it had applied for manufacturing and marketing approval with Japan's Ministry of Health, Labor and Welfare; U.S. FDA and the European Medicines Agency for eribulin for the treatment of locally advanced and metastatic breast cancer

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

The diet pill was not approved or recommended for use in about 90 percent of patients in the trial that triggers the warning, Abbott says.

Related Content

UsernamePublicRestriction

Register

SC073414

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel